{"id":"512975ab51cb","type":"article","url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","title":"Edoxaban bij AF met bioprothese-hartkleppen: trombo-emboliepreventie","title_en":"Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["klepprothese","trombose","veneuze-trombose"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.116.026714","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.116.026714","authors":["Anthony P Carnicelli","Raffaele De Caterina","Jonathan L Halperin","Giulia Renda","Christian T Ruff","Marco Trevisan","Francesco Nordio","Michele F Mercuri","Elliott Antman","Robert P Giugliano"],"significance":7,"published":"2017-03-28","source_date":"2017-03-28","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/","https://hartvaat.nl/kennis/antistolling/doacs-overzicht/"],"congress":"","summary_en":"This study of edoxaban in AF patients with bioprosthetic heart valves expanded the evidence base for DOAC use beyond native valve disease, contributing to the growing data supporting anticoagulation alternatives to warfarin in prosthetic valve patients.","created":"2026-07-03T10:26:37Z","updated":"2026-07-03T13:25:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar edoxaban voor preventie van trombo-embolie bij AF-patiënten met bioprothese-hartkleppen. Verruimt de evidence base voor DOAC-gebruik bij klepprothesen.","abstract_original":""}